Santhera Pharmaceuticals and Cold Spring Harbor Laboratory (CSHL) have entered a collaboration to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE), as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome (ARDS).   Researchers at CSHL are part of a consortium called the ‘NETwork to target neutrophils in COVID-19’. This NETwork will study the role of neutrophils and neutrophil extracellular traps (NETs) in t...